Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D002117:Calcitriol; D002118:Calcium / Q000097:blood / Q000652:urine; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007408:Intestinal Absorption; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011859:Radiography; D006435:Renal Dialysis
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002118:Calcium